Page 138 - 《中国药房》2024年10期

macol Sin，2023，44（5）：1066-1082. [32] WANG Q J，BIN C，XUE Q，et al. GSTZ1 sensitizes hepa‐
[24] FENG J，DAI W Q，MAO Y Q，et al. Simvastatin tocellular carcinoma cells to sorafenib-induced ferroptosis
resensitizes hepatocellular carcinoma cells to sorafenib by via inhibition of NRF2/GPX4 axis[J]. Cell Death Dis，
inhibiting HIF-1α/PPAR-γ/PKM2-mediated glycolysis[J]. 2021，12（5）：426.
J Exp Clin Cancer Res，2020，39（1）：24. [33] MA L，LI G X，ZHU H Q，et al. 2-Methoxyestradiol syner‐
[25] YAO J W，MAN S L，DONG H H，et al. Combinatorial gizes with sorafenib to suppress hepatocellular carcinoma
treatment of Rhizoma Paridis saponins and sorafenib over‐ by simultaneously dysregulating hypoxia-inducible factor-
comes the intolerance of sorafenib[J]. J Steroid Biochem 1 and-2[J]. Cancer Lett，2014，355（1）：96-105.
Mol Biol，2018，183：159-166. [34] PRIETO-DOMÍNGUEZ N， MÉNDEZ-BLANCO C，
[26] FENG J，WU L W，JI J，et al. PKM2 is the target of proan‐ CARBAJO-PESCADOR S，et al. Melatonin enhances
thocyanidin B2 during the inhibition of hepatocellular car‐ sorafenib actions in human hepatocarcinoma cells by in‐
cinoma[J]. J Exp Clin Cancer Res，2019，38（1）：204. hibiting mTORC1/p70S6K/HIF-1α and hypoxia-mediated
[27] HARATI R，VANDAMME M，BLANCHET B，et al. mitophagy[J]. Oncotarget，2017，8（53）：91402-91414.
Drug-drug interaction between metformin and sorafenib [35] YANG Q，GUO X T，YANG L L. Metformin enhances the
alters antitumor effect in hepatocellular carcinoma cells effect of regorafenib and inhibits recurrence and metasta‐
[J]. Mol Pharmacol，2021，100（1）：32-45. sis of hepatic carcinoma after liver resection via regulating
[28] BORT A，SPÍNOLA E，RODRÍGUEZ-HENCHE N，et al. expression of hypoxia-inducible factors 2α （HIF-2α） and
Capsaicin exerts synergistic antitumor effect with 30 kDa HIV Tat-interacting protein （TIP30）[J]. Med Sci
sorafenib in hepatocellular carcinoma cells through Monit，2018，24：2225-2234.
AMPK activation[J]. Oncotarget，2017，8（50）：87684- [36] ZHANG D，JIANG C W，ZHENG X Y，et al. Normaliza‐
87698. tion of tumor vessels by lenvatinib-based metallo-nano
[29] XU J J，ZHENG L B，CHEN J，et al. Increasing AR by drugs alleviates hypoxia and enhances calreticulin-
HIF-2α inhibitor （PT-2385） overcomes the side effects of mediated immune responses in orthotopic HCC and or-
sorafenib by suppressing hepatocellular carcinoma inva‐ ganoids[J]. Small，2023，19（29）：e2207786.
sion via alteration of pSTAT3，pAKT and pERK signals [37] CHANG C C，DINH T K，LEE Y A，et al. Nanoparticle
[J]. Cell Death Dis，2017，8（10）：e3095. delivery of MnO2 and antiangiogenic therapy to overcome
[30] TURCIOS L，VILCHEZ V，ACOSTA L F，et al. Sorafenib hypoxia-driven tumor escape and suppress hepatocellular
and FH535 in combination act synergistically on hepato‐ carcinoma[J]. ACS Appl Mater Interfaces，2020，12（40）：
cellular carcinoma by targeting cell bioenergetics and mi‐ 44407-44419.
tochondrial function[J]. Dig Liver Dis，2017，49（6）： [38] WANG Y H，WANG Z J，JIA F，et al. CXCR4-guided lipo‐
697-704. somes regulating hypoxic and immunosuppressive micro‐
[31] XU F L，WU X H，CHEN C，et al. SLC27A5 promotes environment for sorafenib-resistant tumor treatment[J].
sorafenib-induced ferroptosis in hepatocellular carcinoma Bioact Mater，2022，17：147-161.
by downregulating glutathione reductase[J]. Cell Death （收稿日期：2023-10-13 修回日期：2024-02-19）
Dis，2023，14（1）：22. （编辑：唐晓莲）

· 1284 · China Pharmacy 2024 Vol. 35 No. 10 中国药房 2024年第35卷第10期